Get started
Author

Nathan Vastesaeger

A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis
2009 · Nathan Vastesaeger, Stephen Xu, et al. · Lara D. Veeken · 243
PDF
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1
2013 · J Sieper, J Lenaerts, et al. · Annals of the Rheumatic Diseases · 210
PDF
Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
2009 · Bert Vander Cruyssen, Elisa Muñoz-Gomariz, et al. · Lara D. Veeken · 209
PDF
Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
2011 · Asta Baranauskaite, Helena Raffayová, et al. · Annals of the Rheumatic Diseases · 197
PDF
Predicting the outcome of ankylosing spondylitis therapy
2011 · Nathan Vastesaeger, Désirée van der Heijde, et al. · Annals of the Rheumatic Diseases · 192
PDF
The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
2007 · Bert Vander Cruyssen, Clio Ribbens, et al. · Annals of the Rheumatic Diseases · 127
PDF
Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study
2012 · Joachim Sieper, Shankar Srinivasan, et al. · Annals of the Rheumatic Diseases · 114
Hip disease in ankylosing spondylitis
2013 · Bert Vander Cruyssen, Nathan Vastesaeger, et al. · Current Opinion in Rheumatology · 94
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
2005 · Bert Vander Cruyssen, Stijn Van Looy, et al. · Arthritis Research & Therapy · 92
PDF
Classification and management of allergic rhinitis patients in general practice during pollen season
2006 · H. Van Hoecke, N. Vastesaeger, et al. · Allergy · 83
PDF
Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome
2009 · ANNELIES BOONEN, BERT vander CRUYSSEN, et al. · The Journal of Rheumatology · 69
PDF
Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2
2013 · J Sieper, J Lenaerts, et al. · Annals of the Rheumatic Diseases · 63
PDF
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
2006 · Bert Vander Cruyssen, Stijn Van Looy, et al. · Arthritis Research & Therapy · 53
PDF
Association of Inflammatory Bowel Disease and Acute Anterior Uveitis, but Not Psoriasis, With Disease Duration in Patients With Axial Spondyloarthritis
2018 · Gaëlle Varkas, Nathan Vastesaeger, et al. · Arthritis & Rheumatology · 42
ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy
2014 · Nathan Vastesaeger, Bert Vander Cruyssen, et al. · Reumatología Clínica · 39
Is the Allergic Rhinitis and its Impact on Asthma classification useful in daily primary care practice?
2006 · H VANHOECKE, N VASTESAEGER, et al. · Journal of Allergy and Clinical Immunology · 39
PDF
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study
2013 · Bernard Combe, Bhaskar Dasgupta, et al. · Annals of the Rheumatic Diseases · 31
PDF
An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases
2019 · Antoine Vanier, Josef S Smolen, et al. · Lara D. Veeken · 28
Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria
2006 · JM Lachapelle, J Decroix, et al. · Journal of the European Academy of Dermatology and Venereology · 28
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab
2016 · Nathan Vastesaeger, Abraham Garcia Kutzbach, et al. · Lara D. Veeken · 25
PDF
Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis.
2015 · Hendrik Schulze-Koops, Roberto Giacomelli, et al. · PubMed · 25
Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics
2016 · Joachim Sieper, Martin Rudwaleit, et al. · Lara D. Veeken · 21
Measuring joint involvement in polyarticular psoriatic arthritis: An introduction of alternatives
2010 · M. Englbrecht, Y. Wang, et al. · Arthritis Care & Research · 16
Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO‐VADIS study, a large, prospective real‐life cohort
2019 · Pascal Claudepierre, Filip Van den Bosch, et al. · International Journal of Rheumatic Diseases · 14
PDF
Patient and Physician Expectations of Add‐On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes
2014 · Bhaskar Dasgupta, Bernard Combe, et al. · Arthritis Care & Research · 13
Works count: 88
Citation count: 2,164
H-index: 21
I10-index: 28
Year
Topic
Type